Latest / Community Health Media
Dr. Bill Gradishar & Dr. Tiffany Traina - Is First-Line mTNBC Changing? Datopotamab Deruxtecan vs Sacituzumab Govitecan Explained
In this deep-dive conversation, Dr. Bill Gradishar and Dr. Tiffany Traina break down two pivotal first-line trials reshaping treatment for metastatic triple-negative breast cancer.
They explore TROPION-Breast02 and ASCENT-03, unpacking progression-free survival, overall survival, response rates, toxicity profiles, and what truly differentiates datopotamab deruxtecan from sacituzumab govitecan in real-world practice.
From refractory disease and disease-free interval definitions to logistics, crossover design, brain metastases, and patient-centered decision-making, this discussion offers…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.